Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi Biologics’ Novel Bioprocessing Platform Offers Higher Yields, Lower Costs

publication date: Oct 17, 2023

WuXi Biologics, a global CRDMO headquartered in Shanghai, launched a proprietary bioprocessing platform, WuXiUI™, that features a 3 to 6-fold increase in productivity and a 60-80% savings in cost of goods sold compared to traditional fed-batch processes in single-use bioreactors. To provide those results, WuXi Bio developed an innovative ultra-intensified intermittent-perfusion fed-batch (UI-IPFB) strategy for WuXiUI™. The process improves the productivity and quality of different CHO or other mammalian cell lines and can be used for mAbs, bispecifics and recombinant proteins, according to the company. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital